{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:27Z","timestamp":1787003547857,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"The Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19fk0210035"],"award-info":[{"award-number":["JP19fk0210035"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is no universal recommendation for managing the reactivation of HBV in patients with resolved HBV infection treated with anti-CD20 monoclonal antibodies for B-cell non-Hodgkin lymphoma. This study compared the cost-effectiveness of two commonly used strategies: prophylactic anti-HBV nucleos(t)ide analog therapy (Pro NAT), and HBV DNA monitoring followed by on-demand antiviral therapy (HBV DNA monitoring). Using a decision tree model, the incremental cost-effectiveness ratio (ICER) expressed as cost per quality-adjusted life-year (QALY) gained was calculated. The threshold for cost-effectiveness was set at 5,000,000 JPY, equivalent to 45,662 USD. In a base\u2013case analysis, HBV DNA monitoring was found to be more cost-effective based on the calculation of ICER as 132,048 USD per QALY, a value that far exceeds 45,662 USD. The same results were consistently obtained by a one-way deterministic sensitivity analysis, even after changing each parameter value within the predetermined range. A probabilistic sensitivity analysis with 10,000 simulations also revealed that HBV DNA monitoring is more cost-effective than Pro NAT in 96.8% of cases. Therefore, this study suggests that HBV DNA monitoring is an appropriate managing measure in Japan from a cost-effectiveness perspective.<\/jats:p>","DOI":"10.1038\/s41598-022-10665-3","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T10:17:41Z","timestamp":1651745861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Misuzu","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"10665_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00535-010-0331-4","volume":"46","author":"S Kusumoto","year":"2011","unstructured":"Kusumoto, S., Tanaka, Y., Ueda, R. & Mizokami, M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J. Gastroenterol. 46, 9\u201316. https:\/\/doi.org\/10.1007\/s00535-010-0331-4 (2011).","journal-title":"J. Gastroenterol."},{"key":"10665_CR2","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/asheducation-2014.1.576","volume":"576\u2013583","author":"S Kusumoto","year":"2014","unstructured":"Kusumoto, S. & Tobinai, K. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematol. Am. Soc. Hematol. Educ. Program 576\u2013583, 2014. https:\/\/doi.org\/10.1182\/asheducation-2014.1.576 (2014).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10665_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800 (2018).","journal-title":"Hepatology"},{"key":"10665_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/jco.2015.61.3745","volume":"33","author":"JP Hwang","year":"2015","unstructured":"Hwang, J. P. et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J. Clin. Oncol. 33, 2212\u20132220. https:\/\/doi.org\/10.1200\/jco.2015.61.3745 (2015).","journal-title":"J. Clin. Oncol."},{"key":"10665_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K. & Falck-Ytter, Y. T. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148, 215\u2013219. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039 (2015).","journal-title":"Gastroenterology"},{"issue":"370\u2013398","key":"10665_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL,. Clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(370\u2013398), 2017. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"10665_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10157-011-0464-7","volume":"15","author":"W Ohishi","year":"2011","unstructured":"Ohishi, W. & Chayama, K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin. Exp. Nephrol. 15, 634\u2013640. https:\/\/doi.org\/10.1007\/s10157-011-0464-7 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"10665_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","volume":"133","author":"S Kusumoto","year":"2019","unstructured":"Kusumoto, S. et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133, 137\u2013146. https:\/\/doi.org\/10.1182\/blood-2018-04-848044 (2019).","journal-title":"Blood"},{"key":"10665_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto, S. et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: A prospective observational study. Clin. Infect. Dis. 61, 719\u2013729. https:\/\/doi.org\/10.1093\/cid\/civ344 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"10665_CR10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura, T., Tanaka, E., Kiyosawa, K. & Kumada, H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin. Infect. Dis. 47, e52-56. https:\/\/doi.org\/10.1086\/590968 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"10665_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2169\/naika.107.26","volume":"107","author":"T Umemura","year":"2018","unstructured":"Umemura, T. Strategies for reactivation of hepatitis B. J. Jpn. Soc. Intern. Med. 107, 26\u201331 (2018).","journal-title":"J. Jpn. Soc. Intern. Med."},{"key":"10665_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/jmv.24423","volume":"88","author":"Y Cho","year":"2016","unstructured":"Cho, Y. et al. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin\u2019s lymphoma. J. Med. Virol. 88, 1010\u20131017. https:\/\/doi.org\/10.1002\/jmv.24423 (2016).","journal-title":"J. Med. Virol."},{"key":"10665_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clml.2018.11.008","volume":"19","author":"WP Liu","year":"2019","unstructured":"Liu, W. P. et al. Prophylactic use of entecavir for lymphoma patients with past hepatitis B virus infection: A randomized controlled trial. Clin. Lymphoma Myeloma Leuk. 19, 103\u2013108. https:\/\/doi.org\/10.1016\/j.clml.2018.11.008 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10665_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/phar.2508","volume":"41","author":"CJ Tan","year":"2021","unstructured":"Tan, C. J. et al. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy 41, 332\u2013341. https:\/\/doi.org\/10.1002\/phar.2508 (2021).","journal-title":"Pharmacotherapy"},{"key":"10665_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jfma.2019.05.027","volume":"119","author":"HH Tsou","year":"2020","unstructured":"Tsou, H. H. et al. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J. Formos. Med. Assoc. 119, 335\u2013344. https:\/\/doi.org\/10.1016\/j.jfma.2019.05.027 (2020).","journal-title":"J. Formos. Med. Assoc."},{"key":"10665_CR16","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/jco.2014.56.7081","volume":"32","author":"WK Seto","year":"2014","unstructured":"Seto, W. K. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 32, 3736\u20133743. https:\/\/doi.org\/10.1200\/jco.2014.56.7081 (2014).","journal-title":"J. Clin. Oncol."},{"key":"10665_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","volume":"69","author":"HC Yang","year":"2018","unstructured":"Yang, H. C. et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J. Hepatol. 69, 286\u2013292. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.033 (2018).","journal-title":"J. Hepatol."},{"key":"10665_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2021.1948034","volume":"29","author":"SN Pei","year":"2021","unstructured":"Pei, S. N. et al. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk. Lymphoma 29, 1\u20138. https:\/\/doi.org\/10.1080\/10428194.2021.1948034 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"10665_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 16, 231\u2013250. https:\/\/doi.org\/10.1016\/j.jval.2013.02.002 (2013).","journal-title":"Value Health"},{"key":"10665_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/blt.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram, M. Y. et al. Cost-effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925\u2013930. https:\/\/doi.org\/10.2471\/blt.15.164418 (2016).","journal-title":"Bull. World Health Organ."},{"key":"10665_CR21","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1055\/s-0038-1672185","volume":"2","author":"LA de Jong","year":"2018","unstructured":"de Jong, L. A. et al. Extended treatment with apixaban for venous thromboembolism prevention in the Netherlands: Clinical and economic effects. TH Open 2, e315\u2013e324. https:\/\/doi.org\/10.1055\/s-0038-1672185 (2018).","journal-title":"TH Open"},{"key":"10665_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa, T. et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: What is the threshold of cost effectiveness?. Health Econ. 19, 422\u2013437. https:\/\/doi.org\/10.1002\/hec.1481 (2010).","journal-title":"Health Econ."},{"key":"10665_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1536\/ihj.17-365","volume":"58","author":"S Kodera","year":"2017","unstructured":"Kodera, S. et al. Cost-Effectiveness analysis of cardiovascular disease treatment in Japan. Int. Heart J. 58, 847\u2013852. https:\/\/doi.org\/10.1536\/ihj.17-365 (2017).","journal-title":"Int. Heart J."},{"key":"10665_CR24","unstructured":"Ministry of Health, Labour and Welfare, Government of Japan. Abridged life tables for Japan 2019 https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/lifetb19\/dl\/lifetb19-06.pdf (2019)."},{"key":"10665_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/s0140-6736(11)60828-3","volume":"378","author":"N Ikegami","year":"2011","unstructured":"Ikegami, N. et al. Japanese universal health coverage: Evolution, achievements, and challenges. Lancet 378, 1106\u20131115. https:\/\/doi.org\/10.1016\/s0140-6736(11)60828-3 (2011).","journal-title":"Lancet"},{"key":"10665_CR26","unstructured":"OECD. OECD Stats. https:\/\/stats.oecd.org\/Index.aspx?DataSetCode=HEALTH_REAC."},{"key":"10665_CR27","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/hep.26718","volume":"59","author":"C Hsu","year":"2014","unstructured":"Hsu, C. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology 59, 2092\u20132100. https:\/\/doi.org\/10.1002\/hep.26718 (2014).","journal-title":"Hepatology"},{"key":"10665_CR28","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/jco.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang, Y. H. et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J. Clin. Oncol. 31, 2765\u20132772. https:\/\/doi.org\/10.1200\/jco.2012.48.5938 (2013).","journal-title":"J. Clin. Oncol."},{"key":"10665_CR29","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","volume":"20","author":"N Fukushima","year":"2009","unstructured":"Fukushima, N. et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann. Oncol. 20, 2013\u20132017. https:\/\/doi.org\/10.1093\/annonc\/mdp230 (2009).","journal-title":"Ann. Oncol."},{"key":"10665_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795 (2002).","journal-title":"N. Engl. J. Med."},{"key":"10665_CR31","first-page":"625","volume":"62","author":"T Fukuda","year":"2013","unstructured":"Fukuda, T. et al. Guideline for economic evaluation of healthcare technologies in Japan. J. Natl. Inst. Public Health 62, 625\u2013640 (2013).","journal-title":"J. Natl. Inst. Public Health"},{"key":"10665_CR32","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3109\/10428194.2014.991922","volume":"56","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y. et al. Lymphocyte\/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leuk. Lymphoma 56, 2357\u20132364. https:\/\/doi.org\/10.3109\/10428194.2014.991922 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"10665_CR33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2015.137","volume":"50","author":"S Kurosawa","year":"2015","unstructured":"Kurosawa, S. et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant. 50, 1241\u20131249. https:\/\/doi.org\/10.1038\/bmt.2015.137 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"10665_CR34","unstructured":"Hirao, T. Research on medical economic evaluation of various measures related to viral liver disease https:\/\/mhlw-grants.niph.go.jp\/project\/23533\/1 (2014)."},{"key":"10665_CR35","first-page":"282","volume":"3","author":"C Trey","year":"1970","unstructured":"Trey, C. & Davidson, C. S. The management of fulminant hepatic failure. Prog. Liver Dis. 3, 282\u2013298 (1970).","journal-title":"Prog. Liver Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10665-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:32:07Z","timestamp":1669325527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10665"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10665-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7365"}}